Pharma Giant Roche Buys 89bio for up to $3.5 Billion to Fight Fatty Liver Disease

Pharma giant Roche bought 89bio for up to $3.5B. The focus is pegozafermin, a promising drug for treating MASH (severe fatty liver disease). This deal positions Roche to transform care in metabolic diseases. Shares of 89bio surged 85% on Thursday.